egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

Company to focus on improving the quality of care for all cardiovascular patients in the U.S. 

ALISO VIEJO, Calif. – May 17, 2022 – On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. today announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).

There are an estimated 126 million adults affected by cardiovascular (CV) disease in the U.S.ⁱ The burden of CV disease is only continuing to increase, leaving hospital systems with tens of thousands of patients to manage. Atrial fibrillation (AF), a significant contributor of cardiovascular disease, is expected to grow to more than 12 million cases annually in the U.S. by 2030ⁱⁱ, and can result in stroke, heart failure (HF) and even death.

egnite’s expansion into CV disease is driven by an urgent need to improve the quality of care for every CV patient in the U.S. The company’s decision to focus on AF first is based on an early analysis of over 154,000 patients with the condition across six institutions from egnite’s proprietary database, which observed:

• 52% of potentially eligible patients with AF and an elevated risk of stroke were not prescribed anticoagulation.
• 10% increase in 3-year survival rates observed for patients receiving anticoagulation.

“Our vision is to identify and improve the quality of care for every cardiovascular patient in the U.S.,” said Joel Portice, president and chief executive officer of egnite. “To achieve this expansive goal, we are focused on delivering meaningful solutions that advance the cardiovascular health of our society and elevate the role of data and digital technology in critical healthcare decisions.”

egnite’s CardioCare platform will now expand beyond VHD and HF to include AF, acting as a hospital’s single-source solution to help hospitals prioritize care and resources, so they can better identify patients who could benefit from guideline-directed therapy.

“We are seeing more and more AF patients with an elevated risk of stroke. While clinicians already have several therapeutic options for stroke prevention, egnite’s expansion into CV disease now offers physicians artificial intelligence tools to identify their AF patient population in need of anticoagulation treatment based on their risk of stroke,” said Glenn Barnhart, M.D., chief medical officer of egnite. “As we continue to focus on delivering meaningful improvements in structural heart patient care, we’re excited about the potential of the CardioCare program to become the new standard for how we manage CV patients more broadly.”

Since egnite’s VHD prevalence abstract, two more manuscripts have been accepted and are in press in Intelligence Based Medicine leveraging over 1 million echocardiograms from egnite’s de-identified database. egnite is using this data to transform healthcare delivery.

About egnite, Inc.

egnite is an advanced technology digital health company, spun out from Edwards Lifesciences, focused on delivering meaningful improvements in patient care and advancing the cardiovascular health of our society. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company’s flagship AI platform, CardioCare, has partnered with over 50 hospitals nationwide and leverages the program’s big data analytics platform of over one million echocardiograms to elevate the standard of patient care. The company is based in Aliso Viejo, Calif., for more information, visit www.egnitehealth.com.